Lombard Odier Asset Management (USA)’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-2,379
Closed -$289K 239
2025
Q3
$289K Sell
2,379
-27
-1% -$3.04K 0.02% 368
2025
Q2
$251K Buy
+2,406
New +$255K 0.02% 332
2017
Q1
Sell
-250,000
Closed -$1.69M 209
2016
Q4
$1.69M Sell
250,000
-78,061
-24% -$548K 0.21% 114
2016
Q3
$2.58M Sell
328,061
-13,729
-4% -$104K 0.24% 122
2016
Q2
$2.58M Buy
341,790
+9,400
+3% +$86.6K 0.31% 88
2016
Q1
$2.86M Sell
332,390
-8,702
-3% -$79.9K 0.39% 94
2015
Q4
$3.11M Buy
+341,092
New +$3M 0.3% 103

Other funds holding AXSM

Lombard Odier Asset Management (USA)'s AXSM Position: Q4 2025 in Review

Lombard Odier Asset Management (USA) sold out of Axsome Therapeutics (AXSM) in Q4 2025, closing a stake of 2,379 shares — an estimated $289K sold.

Lombard Odier Asset Management (USA) first reported a position in AXSM in Q4 2015 and held it in 7 quarters. The position peaked at $3.11M in Q4 2015. 398 funds tracked by Wall St. Rank hold AXSM as of Q4 2025.

  • Lombard Odier Asset Management (USA) reported no remaining Axsome Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 2,379 Axsome Therapeutics shares in Q4 2025, an estimated $289K.
  • Lombard Odier Asset Management (USA) first reported a position in Axsome Therapeutics in Q4 2015 and held it in 7 quarters.
  • Lombard Odier Asset Management (USA)'s Axsome Therapeutics position peaked at $3.11M in Q4 2015.
  • 398 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2025.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q4 2025, filed 17 Feb 2026.